Eli Lilly and Company $LLY Shares Acquired by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 6.7% in the third quarter, Holdings Channel.com reports. The firm owned 51,918 shares of the company’s stock after buying an additional 3,256 shares during the period. Foundations Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $39,613,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in LLY. Cloud Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth approximately $77,000. AE Wealth Management LLC grew its holdings in Eli Lilly and Company by 26.7% during the 3rd quarter. AE Wealth Management LLC now owns 86,435 shares of the company’s stock worth $65,952,000 after acquiring an additional 18,200 shares in the last quarter. Archer Investment Corp increased its position in shares of Eli Lilly and Company by 172.2% in the 3rd quarter. Archer Investment Corp now owns 7,582 shares of the company’s stock worth $5,785,000 after purchasing an additional 4,797 shares during the last quarter. LRI Investments LLC raised its stake in shares of Eli Lilly and Company by 32.1% in the 3rd quarter. LRI Investments LLC now owns 2,594 shares of the company’s stock valued at $1,979,000 after purchasing an additional 630 shares in the last quarter. Finally, Financial Security Advisor Inc. raised its stake in shares of Eli Lilly and Company by 0.6% in the 3rd quarter. Financial Security Advisor Inc. now owns 4,017 shares of the company’s stock valued at $3,065,000 after purchasing an additional 25 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Large AI and oncology upside — company coverage highlights a ~$1B collaboration with Nvidia to accelerate drug discovery and an expanded oncology pipeline (including recent regulatory advances) that could fuel 2026 revenue and pipeline value. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Positive Sentiment: Major gene‑editing collaboration — Lilly signed a deal worth up to ~$1.12B with Seamless Therapeutics to develop programmable recombinase therapies for hearing loss, expanding durable‑therapy optionality on its R&D roadmap. Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
• Positive Sentiment: Strong earnings track record — multiple Zacks pieces flag Lilly’s history of earnings beats and Wall Street expectations for EPS growth ahead of the next report, supporting potential near‑term upside on another beat. Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Investor narratives and bullish research — several analyst and bull‑case writeups point to LLY as a long‑term growth name (GLP‑1 leadership, oncology, AI), which supports a buy thesis but is dependent on execution. Eli Lilly and Company (LLY): A Bull Case Theory 
• Neutral Sentiment: Stock is a market focus heading into results — trending coverage and investor interest mean LLY may be more volatile around catalysts (earnings, pipeline readouts). Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
• Negative Sentiment: Intense GLP‑1 competition — data show Novo Nordisk more than doubled U.S. ad spend versus Lilly for Wegovy/Ozempic vs Lilly’s GLP‑1s, implying potential market‑share pressure and the need for higher marketing investment. Exclusive: Novo’s Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
• Negative Sentiment: Drug‑pricing and policy risk — Medicare named several Lilly drugs (including Verzenio) for upcoming price negotiations, which could compress pricing on selected products. US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: Regulatory/operational pushback — hospital groups are contesting a new Lilly 340B claims‑data policy, a dispute that could lead to reputational, contractual or policy‑level headwinds. AHA urges HRSA to stop Eli Lilly’s 340B claims-data submission policy from going into effect
• Negative Sentiment: Immediate market reaction mixed — some coverage notes LLY shares fell even after the gene‑editing announcement, suggesting investors are focusing on near‑term risks (competition, pricing) over long‑term deals. Eli Lilly Stock Drops even after Signing Major $1.1 Billion Gene-Editing Partnership

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Deutsche Bank Aktiengesellschaft lifted their target price on Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. CICC Research upped their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Finally, National Bankshares set a $1,286.00 target price on shares of Eli Lilly and Company in a research note on Monday, December 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Buy” and an average price target of $1,173.91.

Eli Lilly and Company Trading Down 1.5%

NYSE:LLY opened at $1,024.14 on Thursday. The firm has a market capitalization of $968.20 billion, a P/E ratio of 50.10, a P/E/G ratio of 0.79 and a beta of 0.35. The business has a 50 day simple moving average of $1,057.65 and a 200 day simple moving average of $886.06. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company earned $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.